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1. Introduction 
1.1 Fatty acid functions 
Impaired fatty acid metabolism has been implied in a number of diseased states such as 
multiple sclerosis, sudden cardiac death, insulin resistance, atherosclerosis and 
hypertension (Blaak, 2003; Oram & Bornfeldt, 2004; Pilz et al., 2007; Sarafidis & Bakris, 2007; 
Hon et al., 2009a, 2009b). The fatty acid status may be assessed in plasma, platelets, red 
blood cells, white blood cells and brain tissue (Zamaria, 2004, Hon et al., 2009a). However, 
the plasma fatty acid profile may vary considerably, whereas red blood cell membrane fatty 
acids are said to reflect dietary fat intake in relation to the biological half life of cells (Romon 
et al., 1995; Zamaria, 2004). Furthermore, red blood cell membranes, in contrast to other 
cells, lack the desaturase enzymes and must get their fatty acids preformed from plasma 
(Allen et al., 2006). Fatty acids may be saturated, monounsaturated (the n-7 and n-9 fatty 
acid series) or polyunsaturated (the n-3 and n-6 fatty acid series) and membrane fatty acids 
may further be non-esterified or esterified into glycerophospholipids (Koay & Walmsley, 
1999).  
1.1.1 Cell membrane fluidity – Phospholipids  
Cell membrane phospholipids differ in their head-groups and hydrocarbon chains (fatty 
acids) (Hazel & Williams, 1990; Williams, 1998; Barenholz, 2002). Their polar head-groups 
can be choline, ethanolamine, serine, inositol, inositol phosphates or glycerol (Koay & 
Walmsley, 1999). Cell membrane phospholipids as well the type of fatty acids contained 
within the different phospholipid fractions are responsible for a variety of cellular functions 
(Manzoli, 1970; Caret et al. 1997; Williams, 1998). Cell membrane phospholipids determine 
membrane structure and fluidity. Phosphatidylethanolamine phospholipids are ordered-
crystalline-phase lipids and can pack closely in membranes, while phosphatidylcholine 
phospholipids are liquid-crystalline-phase lipids, and do not pack close in the membrane 
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(Harlos & Eibl, 1981; Williams, 1998; Hamai et al. 2006). A combination of ordered-
crystalline-phase lipids and liquid-crystalline-phase lipids are needed in cell membranes to 
regulate membrane fluidity.  
1.1.2 Cell membrane fluidity – Fatty acids 
Polyunsaturated fatty acids influence membrane fluidity, are involved with 
neurotransmission and prostaglandin formation, and are involved in enzyme and receptor 
expression (Horrobin & Manku, 1990; Horrobin, 1999; De Pablo & De Cienfuegos, 2000; 
Nakamura & Nara, 2004; Zamaria, 2004). Similar to the role of cell membrane 
phospholipids, a balance in the saturated and unsaturated fatty acids composition is needed 
for optimal membrane fluidity (Allen et al. 2006). Saturated fatty acids contain single 
carbon-carbon bonds, while mono- and polyunsaturated fatty acids contain double carbon-
carbon bonds which allow for greater flexibility of these chains (Horrobin, 1999; Allen et al. 
2006). Membrane fluidity is an important function of cell membranes and organisms adjust 
the fluidity of their cellular membranes in response to changes in their physiochemical 
environment (Hazel & Williams, 1990; Williams, 1998; Barenholz, 2002; Allen et al. 2006). In 
this regard, phagocytosis is an important mechanism in many cells for the elimination of 
micro-organisms or foreign particles, and membrane fluidity plays an important role in this 
process (De Pablo & De Cienfuegos, 2000). Although the underlying cause of multiple 
sclerosis remains unknown, both an auto-immune and viral aetiology has been 
hypothesized as contributing factors to the disease (Stinissen et al. 1997; Brown, 2001; 
Hunter & Hafler, 2000). 
1.1.3 Fatty acids in inflammation and infection 
Polyunsaturated fatty acids are also precursors for eicosanoid production. Eiosanoids are 
inflammatory mediators of inflammation and their functions depend on each precursor fatty 
acid (Horrobin & Manku, 1990; De Pablo & De Cienfuegos, 2000; Zamaria, 2004). The effects 
of monounsaturated fatty acids on eicosanoid metabolism are less clear than that of the 
polyunsaturated fatty acids (Harwood & Yaqoob, 2002). However, studies suggest that diets 
rich in monounsaturated fatty acids may decrease the expression of adhesion molecules on 
peripheral blood mononuclear cell membranes, and may therefore have specific anti-
inflammatory effects (Yaqoob et al. 1998; Harwood & Yaqoob, 2002). Saturated fatty acids 
have been shown to display anti-viral and -bacterial properties (Sands, 1977; Cordo et al. 
1999; Narasimhan et al. 2006).  
1.1.4 Fatty acid supplementation 
It is important to be able to separate and quantify the individual fatty acids because they 
differ in structure and function. Altered lipid metabolism in the cell membrane is believed to 
contribute to central nervous system injury (Adibhatla & Hatcher, 2007) and influences the 
function of immune cells (Calder, 2007). Fatty acids have been implicated in the 
pathogenesis and treatment of multiple sclerosis (Zamaria, 2004; Harbige & Sharief, 2007). 
However, although some studies reported an improvement in symptoms during fatty acid 
supplementation (Bates et al. 1978; Nordvik et al. 2000; Weinstock-Guttman et al. 2005; 
Harbige & Sharief, 2007) others found no improvement in the disease progression of 
patients (Paty et al. 1978; Farinotti et al. 2007). Therefore, it is important to investigate fatty 
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acid metabolic abnormalities and possible treatment with fatty acid supplements in a 
disease such as multiple sclerosis carefully and comprehensively. 
1.2 Gas chromatography applications of fatty acids 
The ability of gas chromatography to separate and quantify fatty acids makes it possible to 
measure fatty acids in human cells. Generally, the results obtained from gas 
chromatography analysis are expressed either as absolute amounts or relative percentages. 
The preferred method for the quantification of fatty acids is in absolute amounts, using 
calibration methods and internal standards. However, quantification in relative percentages 
may in some cases supply additional information and this method should therefore not be 
rejected without evaluating its potential. This paper discusses the discrepancies arising 
when reporting results quantified in either absolute amounts or relative percentages when 
investigating the fatty acid profile in a diseased state. 
1.3 Fatty acids quantified in relative percentages and in absolute amounts 
It is important to know whether fatty acids are present in optimum amounts in relation to 
one another in a diseased state. For example, fatty acids from the n-6 and n-3 fatty acid 
series fulfil different functions as precursors for pro- and anti-inflammatory mediators 
respectively. Prostaglandin E2, which is derived from the metabolism of C20:4n-6 (see Table 
1 for common names) is highly pro-inflammatory and prostaglandin E1 derived from the 
metabolism of C20:3n-6 has intermediate properties (Horrobin & Manku, 1990; Simopoulos, 
2002; Bagga et al., 2003; Haag, 2003). In contrast, prostaglandin E3 derived from the 
metabolism of C20:5n-3 and docosanoids derived from the metabolism of C22:6n-3 have 
anti-inflammatory properties (Bagga et al., 2003; Haag, 2003; Zamaria, 2004; Farooqui et al., 
2007; Chen et al., 2008). The n-3 fatty acids, C20:5n-3 and C22:6n-3 compete with the n-6 
fatty acid, C20:4n-6 for enzymatic metabolism (Simopoulos, 2002; Bagga et al., 2003; Culp et 
al., 1979; Calder, 2007) and in a disease such as multiple sclerosis which is inflammatory in 
nature, it could be useful to know whether the n-6 and n-3 fatty acids are present in relative 
percentages comparable to that from control subjects.  
The long-chain n-6 and n-3 polyunsaturated fatty acids are also required in large amounts in 
the brain, which requires four times the amount of C20:4n-6 than C22:6n-3 4 times the 
amount of C20:4n-6 than C22:6n-3 on a daily basis (Harbige & Sharief, 2007; Rapoport et al., 
2007). Furthermore, the composition of membrane phospholipids and their fatty acids 
determines the degree of membrane fluidity and the degree of fatty acid unsaturation plays 
an important role in maintaining required physiological levels of fluidity (Mouritsen & 
Jorgensen, 1998; Zamaria, 2004). In a diseased state it may be useful to know their relative 
percentages as measured against that of total fatty acids present as compared to that of 
control subjects. However, using relative percentages as a measure could bias results when 
comparisons are made between subjects. Comparing similar percentages of different 
absolute values could become misleading when these absolute values differ substantially 
and it has been suggested that relative percentages do not represent a true reflection of the 
different fatty acid compounds present in biological fluids/tissue. Absolute values are also 
an indication of the movement of fatty acids between phospholipid classes within the cell 
membrane and could therefore reflect their possible availability for metabolite synthesis, 
particularly inflammatory signalling.  
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1.4 Fatty acids in multiple sclerosis 
Reports on fatty acid composition in blood and brain tissue from patients with multiple 
sclerosis may vary substantially (Harbige & Sharief, 2007; Hon et al., 2009a, 2009b). Cultural 
and ethnic differences as well as dietary variability have been implicated in these differences 
(Harbige & Sharief, 2007). However, a further cause for these differences could possibly be 
related to the quantification method used. Measurement of the fatty acid composition in 
absolute amounts and relative percentages could both be informative, but could well differ 
in the information given. The absolute amounts of fatty acids are identified in relation to the 
phospholipids and membrane content whereas the relative percentage composition is a 
measure of each fatty acid present in relation to the total fatty acids identified, that is 
changes in one fatty acid will affect the percentage of all other fatty acids. Therefore, ideally, 
fatty acid analysis and interpretation should be evaluated according to outcome required. In 
this chapter we evaluate whether the two methods of measurement of fatty acids in control 
subjects would show sufficient agreement and to evaluate possible deviations from these 
relationships in patients with multiple sclerosis. Furthermore, to evaluate the two methods 
of measurement when correlated/associated with inflammation as measured by C-reactive 
protein as well as disease outcome as measured by the Kurtzke Expanded Disability Status 
Scale (Kurtzke, 1983). C-reactive protein is a recognised marker of inflammation and has 
been shown to correlate with infectious episodes and clinical relapses in patients with 
multiple sclerosis (Giovannoni et al., 1996; Giovannoni et al., 2001; Sellner et al., 2008). Thin-
layer chromatography and gas chromatography were used for the extraction and separation 
of lipid classes and quantification of fatty acids in plasma, red blood cell and peripheral 
blood mononuclear cell membranes from control subjects and patients with multiple 
sclerosis (Folch et al., 1957; Gilfillan et al., 1983; Van Jaarsveld et al., 2000; Hon et al., 2009b; 
Hon et al., 2011a).  
2. Methodology 
2.1 Ethics statement 
Ethics approval for the study was obtained from the Health and Applied Sciences Research 
Ethics Committee of the Cape Peninsula University of Technology. Patients with multiple 
sclerosis were contacted and recruited through the Multiple Sclerosis Society, Western Cape 
Branch, South Africa. The study population consisted of 31 female patients with multiple 
sclerosis and 30 age- race- and gender-matched control subjects. Informed written consent 
was obtained from all study participants. All results were treated confidentially. 
2.2 Study population 
The diagnoses of the recruited patients were verified by a neurologist based on clinical, 
laboratory and magnetic resonance imaging findings. Six of the patients had active disease, 
11 had a relapse 5-12 months prior to recruitment and 14 did not relapse for more than a 
year. The number of years since the patients were diagnosed was 7 (11) years (median and 
quartile range). Ten patients were using non-steroidal anti-inflammatory drugs and five 
patients were using immunosuppressive medication. Exclusion criteria included the use of 
interferon, steroids, and fatty acid supplements. 
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2.3 Blood sampling and processing  
Venous blood was collected after an overnight fast into anti-coagulant 
ethylenediaminetetraacetic acid tubes (Beckman Coulter, Cape Town, South Africa). Blood 
was separated into its different components using histopaque-1077 separation medium as 
per manufacturer’s instructions (Sigma-Aldrich, Cape Town, South Africa). Blood was 
layered onto histopague in a ratio of 15 mL blood per 12 mL histopague and centrifuged at 
400 x g for 20 min at room temperature. The plasma layer was kept, spun twice at 1500 x g 
for 5 min to remove platelet contaminants, and frozen in 1 mL aliquots. The peripheral 
blood mononuclear cell interface was recovered, washed twice with 0.85 % saline solution, 
resuspended in 1 mL of a 0.85 % saline solution and frozen. Three mL red blood cells were 
washed twice with 0.85 % saline solution and frozen as packed cells without added saline. 
The samples were frozen at -80°C immediately after separation of blood fractions. A 0.85 % 
saline solution was used in this study instead of the prescribed balanced phosphate buffered 
saline solution as additional tests such as membrane phosphate determination were to be 
carried out at a later stage.  
Solvent mixtures and thin-layer chromatography was used for the extraction and separation 
of fatty acids respectively, with further conversion to fatty acid methyl esters for 
quantification by gas chromatography as described by Folch et al. (1957), Gilfillan et al. 
(1983), Van Jaarsveld et al. (2000), Hon et al. (2009b), Hon et al. (2011a). The following 
sections summarises the methodology used for quantification of the fatty acids in human 
tissue, plasma, red blood cell and peripheral blood mononuclear cell membranes. 
2.4 Thin – Layer chromatography 
The plasma, red blood cell and peripheral blood mononuclear cell membrane lipids were 
extracted according to a modified method of Folch et al. (1957), Van Jaarsveld et al. (2000), 
and described in Hon et al. (2009b), Hon et al. (2011a). All the extraction solvents were of 
high-performance liquid chromatography-grade and contained 0.01 % butylated 
hydroxytoluene (Sigma-Aldrich, Cape Town, South Africa) as an antioxidant. The red blood 
cell samples were extracted and the dried lipid residue resuspended in 80 µl 
chloroform/methanol (ratio 2:1 v/v) for thin-layer chromatography. Of this 20 µl was used 
for esterified fatty acid analysis and 40 µl for non-esterified fatty acid separation on thin-
layer chromatography. The peripheral blood mononuclear cell samples were resuspended in 
70 µl chloroform/methanol; 20 µl was used for esterified fatty acid analysis and 30 µl for 
non-esterified fatty acid analysis. Plasma samples were resuspended in 80 µl 
chloroform/methanol of which 20 µl was used for esterified fatty acid analysis and 30 µl for 
non-esterified fatty acid analysis.  
Neutral lipids (non-esterified fatty acids, mono- di- and triacylglyceryl and cholesteryl fatty 
acid esters) were separated from the total phospholipid fraction by thin-layer 
chromatography on pre-coated silica gel plates (10 x 10 cm), using the solvent system 
petroleum benzene (boiling point 40-60°C)/diethyl ether (peroxide free)/acetic acid (90:30:1; 
v/v/v) (Sigma-Aldrich, Cape Town, South Africa) as previously described (Van Jaarsveld et 
al., 2000). Individual phospholipid classes were separated by thin-layer chromatography on 
pre-coated silica gel plates (10 x 10 cm) using chloroform/petroleum 
benzene/methanol/acetic acid/boric acid (40:30:20:10:1.8; v/v/v/v/w) as solvent (Gilfillan 
et al., 1983).  
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The lipid bands containing phosphatidylcholine (PC), phosphatidylethanolamine (PE), 
phosphatidylserine (PS) and sphingomyelin (SM) were identified by comparison to a known 
mixed phospholipid standard run in parallel to the samples and visualized with long wave 
ultraviolet light after spraying the plates with chloroform/methanol (ratio 1:1; v/v) 
containing 10 mg per 100 mL 2,5-bis-(5´-tert-butylbenzoxazolyl-[2´])thiophene (Sigma 
Chemical Company, Cape Town, South Africa). These bands were scraped off the thin-layer 
chromatography plates and used for further fatty acid analysis. 
Fatty acids 
Abbreviated chemical formulae Common name 
C18:3n-3 Alpha-linolenic acid 
C18:4n-3 Stearidonic acid 
C20:4n-3 Eicosatetraenoic 
C20:5n-3 Eicosapentaenoic acid 
C22:5n-3 Docosapentaenoic acid 
C22:6n-3 Docosahexaenoic acid 
C18:2n-6 Linoleic acid 
C18:3n-6 Gamma-linolenic acid 
C20:2n-6 Eicosadienoic acid 
C20:3n-6 Dihomo-gamma-linolenic acid 
C20:4n-6 Arachidonic acid 
C22:4n-6 Adrenic acid 
C22:5n-6 Docosapentaenoic acid 
C16:1n-7 Palmitoleic acid 
C18:1n-7 Vaccenic acid 
C18:1n-9 Oleic acid 
C20:1n-9 Gadoleic acid 
C14:0 Myristic acid 
C16:0 Palmitic acid 
C18:0 Stearic acid 
C20:0 Arachidic acid 
C22:0 Behenic acid 
C24:0 Lignoceric acid 
Table 1. Abbreviated chemical formulae and common names of major plasma and blood cell 
membrane fatty acids. References: Nightingale et al., 1990; Horrobin, 1999; Pereira et al., 
2003. 
2.5 Gas chromatography 
The lipid fractions scraped off the thin-layer chromatography plates were transmethylated, 
using 5 % sulphuric acid/methanol at 70°C for 2 hours (sphingomyelin fraction: 18 hours) 
(Van Jaarsveld et al., 2000; Hon et al., 2009b; Hon et al., 2011a). After cooling, the resulting 
fatty acid methyl esters were extracted with 1 mL of distilled water and 2 mL of n-hexane. 
The top hexane layer was removed and evaporated to dryness in a waterbath at 37°C under 
nitrogen gas, re-dissolved in carbon disulphide and analyzed by gas chromatography 
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(Finnigan Focus Gas Chromatography, Thermo Electron Corporation, USA, equipped with 
flame ionization detection), using a 30 meter BPX 70 capillary columns of 0.32 mm  internal 
diameter (SGE International Pty Ltd, Australia). Gas flow rates were as follows: nitrogen, 25 
mL per min; air, 250 mL per min; and hydrogen (carrier gas), 25 mL per min and a split ratio 
of 20:1. Temperature programming was linear at 5°C per min, with initial temperature of 
140°C, final temperature 220°C, injector temperature 240°C, and detector temperature 250°C. 
The fatty acid methyl esters were identified by comparison of the retention times to those of 
a standard fatty acid methyl ester mixture (Nu-Chek-Prep Inc., Elysian, Minnesota). The 
individual fatty acid methyl esters were quantified against an internal standard with known 
concentration (C17:0, Sigma-Aldrich, South Africa). Plasma fatty acids were quantified in 
absolute values in µg fatty acids per mL plasma analyzed. Red blood cell membrane fatty 
acids were quantified in absolute values in µg fatty acid per mL packed red blood cells 
analyzed. Peripheral blood mononuclear cell membrane protein was measured and fatty 
acids were quantified against membrane protein present in µg fatty acids per mg protein 
(see protein assay below). All individual fatty acids were also reported as relative 
percentage of the total fatty acids identified. 
2.6 Protein analysis 
The bicinchoninic acid protein determination assay was used to determine the protein 
content of peripheral blood mononuclear cell membranes (Kaushal & Barnes, 1986) for 
quantification of membrane fatty acids. Peripheral blood mononuclear cell membrane lipids 
were quantified against membrane protein present because of the high variation normally 
found in white blood cell counts. Of the starting material prepared in saline, a 200 µl sample 
aliquot was diluted with 2 % sodium dodecyl sulphate solution (Fluka, Sigma-Aldrich, Cape 
Town, South Africa) to denaturate protein prior to protein determination and assayed for 
protein content in triplicate. Bovine serum albumin (Sigma-Aldrich, Cape Town, South 
Africa) was used to prepare a standard curve. Sample and standard optical density was read 
on a spectrophotometer at a wavelength of 562 nm. Sample values were obtained from the 
bovine serum albumin linear standard curve. Peripheral blood mononuclear cell membrane 
fatty acids were quantified against membrane proteins and expressed in µg fatty acids per 
mg protein.  
2.7 Phospholipid determination 
Red blood cell and peripheral blood mononuclear cell membrane phospholipids were 
determined using a colorimetric assay with malachite green dye, as previously described 
(Itaya & Ui, 1966; Smuts et al., 1994). Phospholipid classes, identified and recovered as 
described above, were reduced to inorganic phosphates and quantified according to their 
phosphorous (Pi) content.  
The different factors used for conversion of phosphorous to phospholipids were: for 
phosphatidylcholine: 25.4; phosphatidylethanolamine: 23.22; phosphatidylserine: 25.4; and 
sphingomyelin: 24.21. Red blood cell membrane phospholipid quantification was expressed 
in µg phospholipid per mL packed cells and peripheral blood mononuclear cell membrane 
phospholipid in µg phospholipid per mg protein (see protein assay). 
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2.8 C-reactive protein determination  
Plasma C-reactive protein concentrations were determined in a routine Chemical Pathology 
laboratory using a Beckman nephelometer auto-analyser using reagents from Beckman, 
Cape Town, South Africa. A positive diagnostic value is considered as a C-reactive protein 
value equal to or greater than 5 µg per mL plasma. 
2.9 Statistical analysis 
A statistics programme, STATISTICA 9 {StatSoft, Inc. (2009). STATISTICA} was used to 
perform all statistical analyses. Correlation studies using Spearman’s Rank correlation 
coefficient were used to evaluate the measure of agreement between the two methods 
(absolute amounts and relative percentages) in the plasma, red blood cell and peripheral 
blood mononuclear cell membranes from control subjects and patients with multiple 
sclerosis (Table 2). Linear regression analyses were used to measure strength of association 
between fatty acids quantified in absolute amounts and relative percentages, and C-reactive 
protein as well as the Kurtzke Expanded Disability Status Scale (Tables 3 and 4). The results 
were considered significant if P-values were less than 0.05.  
3. Results  
3.1 Method of measurement comparison  
correlation studies between fatty acids quantified in absolute amounts and relative 
percentages are summarized in Table 2, Figure 1 and Results: sections 3.1.1, 3.1.2 and 3.1.3: 
Overall, the absolute amounts and relative percentage fatty acid composition results were 
moderately and mostly positively associated with each other in both study groups, although 
a number of fatty acids correlated not significantly in both groups (data not shown). 
However, it should be noted that though these correlations were significant, they were not 
strong as most of the R values were less than 0.5. Differences in the strength of association 
between the two study groups are listed below. 
3.1.1 Plasma fatty acids 
SM C20:0 showed significant correlations in controls only, and non-esterified fatty acid 
C18:2n-6 and PC C16:0 showed significance in patients only.  Further, SM C18:0 showed 
weaker correlations in plasma from patients than in controls. Non-esterified fatty acids 
C20:4n-6, C16:0 and C18:0 showed no correlation in either of the two study groups. 
3.1.2 Red blood cell membrane fatty acids 
PS C22:4n-6, SM C16:0 and PS C18:0 showed significant correlations in controls only and PS 
C20:4n-6, PS C22:6n-3, PC C18:1n-9 and non-esterified fatty acid C22:0 were significantly 
associated in patients only. PE C18:0 showed a stronger association between absolute 
amounts and relative percentage fatty acids in red blood cells from patients with multiple 
sclerosis than in control subjects. Furthermore, PE C20:4n-6, PC C16:0, PE C16:0, PC C18:0, 
PE C18:0 and non-esterified fatty acid C16:0 showed no correlation in either of the two study 
groups. 
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 Total group Controls Patients 
 R P-value R P-value R P-value 
Plasma fatty acids
Polyunsaturated fatty acids  
NEFA C18:2n-6 0.42 0.0008 0.31 0.0961 0.48 0.0060 
Saturated fatty acids  
PC C16:0 0.33 0.0095 0.35 0.0601 0.36 0.0469 
SM C18:0 0.64 < 0.0001 0.80 < 0.0001 0.50 0.0039 
SM C20:0 0.49 0.0001 0.65 0.0001 0.34 0.0644 
    
Red blood cell membrane fatty acids
Polyunsaturated fatty acids  
PE C20:4n-6 0.36 0.0041 0.35 0.0583 0.28 0.1245 
PS C20:4n-6 0.40 0.0012 0.17 0.3699 0.50 0.0043 
PS C22:4n-6 0.53 < 0.0001 0.74 < 0.0001 0.18 0.3413 
PS C22:6n-3 0.45 0.0002 0.31 0.0951 0.57 0.0008 
Monounsaturated fatty acids  
PC C18:1n-9 0.40 0.0012 0.31 0.0992 0.47 0.0072 
Saturated fatty acids  
NEFA C22:0 0.41 0.0012 0.27 0.1528 0.45 0.0113 
PC C18:0  0.23 0.0737 0.33 0.0780 0.18 0.3363 
PE C16:0  0.32 0.0118 0.34 0.0622 0.27 0.1373 
PE C18:0  0.34 0.0075 0.30 0.1099 0.35 0.0518 
PS C18:0 -0.34 0.0079 -0.37 0.0461 -0.26 0.1557 
SM C16:0 0.41 0.0011 0.58 0.0009 0.36 0.0509 
    
Peripheral blood mononuclear cell membrane fatty acids
Polyunsaturated fatty acids  
PC C18:2n-6 0.65 < 0.0001 0.32 0.1156 0.81 < 0.0001 
PE C20:4n-6 0.56 < 0.0001 0.38 0.0599 0.69 0.0001 
Monounsaturated fatty acids  
NEFA C18:1n-9 0.69 < 0.0001 0.89 < 0.0000 0.39 0.0463 
PC C18:1n-9 0.62 < 0.0001 0.42 0.0351 0.78 < 0.0001 
Saturated fatty acids  
NEFA C18:0 -0.10 0.4700 -0.43 0.0337 0.08 0.6903 
PE C18:0 0.39 0.0051 0.49 0.0121 0.31 0.13153 
PS C18:0 0.38 0.0064 0.40 0.0448 0.34 0.0924 
SM C16:0 0.51 0.0001 0.24 0.2432 0.69 0.0001 
SM C18:0 0.51 0.0002 0.22 0.3168 0.74 < 0.0001 
Table 2. Method of measurement comparison: correlation studies between fatty acids 
quantified in absolute amounts and relative percentages. Key: NEFAs: Non-esterified fatty 
acids, PC: Phosphatidylcholine, SM: Sphingomyelin, PE: Phosphatidylethanolamine, PS: 
Phosphatidylserine. 
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3.1.3 Peripheral blood mononuclear cell membrane fatty acids 
PE C18:0, PS C18:0 and non-esterified fatty acid C18:0 showed significant correlations in 
controls only and PC C18:2n-6, PE C20:4n-6, SM C16:0 and SM C18:0 were significant in 
patients only. PC C18:1n-9 showed stronger correlations between absolute amounts and 
relative percentage fatty acids in peripheral blood mononuclear cells from patients with 
multiple sclerosis, while non-esterified fatty acid C18:1n-9 showed stronger correlations in 
controls.  
3.2 Differences between plasma, red blood cell and peripheral blood mononuclear cell 
membrane fatty acids from control subjects and patients with multiple sclerosis 
Measures of central tendencies have been published previously. Polyunsaturated fatty acids 
measured in plasma, red blood cell and peripheral blood mononuclear cell membranes from 
control subjects and patients with multiple sclerosis showed similar results when measured 
in absolute values or relative percentages. They include the following: PC C20:4n-6 
quantified in absolute values (Hon et al., 2011a) and relative percentages (data not shown) 
was decreased in plasma from patients. PC C20:4n-6 quantified in absolute values (Hon et 
al., 2009a) and relative percentages (data not shown) was decreased in red blood cell 
membranes from patients. PE C22:4n-6 and PS C22:4n-6 quantified in absolute values as 
well as relative percentages were decreased in peripheral blood mononuclear cell 
membranes from patients with multiple sclerosis (Hon et al., 2009b). 
3.3 Association studies between C-reactive protein and PC fatty acids are 
summarized in Table 3 
3.3.1 Plasma fatty acids 
C-reactive protein showed no association with any of the fatty acids quantified in absolute 
amounts in the PC phospholipid fraction in plasma from controls, but a positive association 
with PC C20:3n-6 in plasma from patients. It showed a weak association with PC C20:3n-6 
quantified in relative percentages in plasma from controls and a strong association in 
plasma from patients similar to that found with the fatty acid quantified in absolute 
amounts. It further showed a positive association with PC C16:1n-7 quantified in relative 
percentages in plasma from controls and an inverse association with PC C18:1n-9 in plasma 
from patients. 
3.3.2 Red blood cell membrane fatty acids 
The C-reactive protein showed a positive association with PC C16:1n-7 (Hon et al., 2010) 
quantified in absolute amounts in the red blood cells from controls and a positive 
association with PC C20:3n-6 in red blood cells from patients. Similar to results for that of 
plasma PC fatty acids, it showed a weak association with PC C20:3n-6 quantified in relative 
percentages in red blood cells from controls and a strong association in red blood cells from 
patients. Also, similar to results for that of plasma PC fatty acids, the C-reactive protein 
showed a positive association with PC C16:1n-7 quantified in relative percentages in red 
blood cells from controls and an inverse association with PC C18:1n-9 in red blood cells 
from patients, but this inverse correlation was also found in red blood cells from controls 
(Hon et al., 2010). 
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 Controls Patients 
 
Absolute  
amounts 
Percentages 
Absolute 
amounts 
Percentages 
 b* P-value b* P-value b* P-value b* P-value 
Plasma fatty acids        
Polyunsaturated fatty acids       
PC C20:3n-6       0.30 0.1242 0.33 0.0973 0.39 0.0378 0.49 0.0071 
Monounsaturated fatty acids       
PC C16:1n-7       0.32 0.1152 0.40 0.0444 0.15 0.4485 0.12 0.5416 
PC C18:1n-9 -0.01 0.9653 -0.12 0.5585 -0.16 0.4044 -0.46 0.0126 
Saturated fatty acids        
PC C18:0             -0.01 0.9570 -0.19 0.3390 0.33 0.0840 0.21 0.2694 
         
Red blood cell membrane fatty acids      
Polyunsaturated fatty acids       
PC C20:3n-6 0.20 0.3059 0.36 0.0625 0.34 0.0679 0.52 0.0041 
PC C22:4n-6 0.18 0.3826 0.37 0.0601 -0.26 0.1759 -0.24 0.2113 
Monounsaturated fatty acids       
PC C16:1n-7 + Association* 0.39 0.0468 No association* 0.14 0.4788 
PC C18:1n-9 No association* -0.34 0.0817 No association* -0.41 0.0264 
         
Peripheral blood mononuclear cell membrane fatty acids    
Polyunsaturated fatty acids       
PC C20:3n-6 0.22 0.3255 0.24 0.2818 0.16 0.4482 0.37 0.0714 
PC C22:4n-6 0.27 0.2262 0.38 0.0773 -0.14 0.5093 0.07 0.7534 
PC C22:5n-6 0.45 0.0358 0.46 0.0326 0.07 0.7629 0.23 0.2806 
PC C20:5n-3 -0.05 0.8133 -0.06 0.7823 -0.36 0.0842 -0.36 0.0944 
Monounsaturated fatty acids       
PC C16:1n-7 + Association* 0.54 0.0095 No association* 0.12 0.5970 
PC C18:1n-7 + Association* 0.42 0.0537 No association* 0.46 0.0230 
PC C18:1n-9 No association* -0.45 0.0353 No association* -0.02 0.9398 
Saturated fatty acids        
PC C14:0 0.30 0.1772 0.29 0.1953 -0.34 0.0992 -0.25 0.2426 
PC C18:0 0.04 0.8744 -0.03 0.8887 -0.47 0.0204 -0.24 0.2694 
PC C20:0 -0.07 0.7563 -0.14 0.5429 -0.36 0.0866 -0.14 0.5003 
PC C22:0 -0.39 0.0762 -0.40 0.0680 -0.16 0.4487 0.04 0.8700 
Table 3. Association studies between C-reactive protein and PC fatty acids in plasma, red 
blood and peripheral blood mononuclear cell membranes. * Results: Hon et al. (2010) 
3.3.3 Peripheral blood mononuclear cell membrane fatty acids 
The C-reactive protein showed a weak association with PC C20:3n-6 quantified in relative 
percentages in peripheral blood mononuclear cell membranes from patients. It showed 
positive associations with PC C22:5n-6, PC C16:1n-7 (Hon et al., 2010) and PC C18:1n-7 (Hon 
et al., 2010) quantified in both absolute amounts and relative percentages in peripheral 
blood mononuclear cell membranes from controls, while only PC C18:1n-7 quantified in 
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relative percentages showed a positive association in peripheral blood mononuclear cell 
membranes from patients. It also showed an inverse association with PC C18:1n-9 
quantified in relative percentages in peripheral blood mononuclear cell membranes from 
controls, in contrast to results in plasma and red blood cells where this association was 
found in patients. 
3.4 Association studies between the Kurtzke Expanded Disability Status Scale and 
fatty acids from patients with multiple sclerosis are summarized in Table 4 
3.4.1 Plasma fatty acids 
The Kurtzke Expanded Disability Status Scale showed near-significant inverse associations 
with non-esterified fatty acid C20:4n-6 and SM C20:0 quantified in relative percentages, but 
not with absolute amounts in plasma from patients. It also showed a significant inverse 
correlation with non-esterified fatty acid C14:0 quantified in relative percentages, but a near-
significant positive association with non-esterified fatty acid C14:0 quantified in absolute 
amounts. 
 Patients with multiple sclerosis
 Absolute amounts Relative percentages  
 b* P-value b* P-value R2 
Plasma fatty acids  
Polyunsaturated fatty acids   
NEFA C20:4n-6 -0.04 0.8188 -0.34 0.0716 0.05 
Saturated fatty acids  
NEFA C14:0 0.42 0.0550 -0.48 0.0307 0.11 
NEFA C16:0 0.26 0.1532 -0.31 0.0869 0.08 
SM C20:0 -0.01 0.9683 -0.34 0.0828 0.05 
  
Red blood cell membrane fatty acids   
Polyunsaturated fatty acids   
PC C20:2n-6 -0.42 0.2154 0.72 0.0397 0.12 
PE C20:3n-6 -0.30 0.2806 0.61 0.0322 0.12 
PS C22:5n-3 -0.06 0.7511 -0.41 0.0320 0.14 
Saturated fatty acids  
PC C16:0 -0.31 0.0771 -0.31 0.077 0.13 
PC C18:0 -0.13 0.4928 0.41 0.0372 0.09 
PE C16:0 -0.06 0.7650 0.34 0.0835 0.04 
  
Peripheral blood mononuclear cell membrane fatty acids  
Polyunsaturated fatty acids   
PE C20:5n-3 0.95 0.1296 -1.10 0.0791 0.06 
Monounsaturated fatty acids   
PC C24:1n-9 2.14 0.0708 -1.99 0.0927 0.07 
Table 4. Association studies between the Kurtzke Expanded Disability Status Scale and 
absolute amounts and relative percentage fatty acids in plasma, red blood cell and 
peripheral blood mononuclear cell membranes from patients with multiple sclerosis  
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3.4.2 Red blood cell membrane fatty acids 
The Kurtzke Expanded Disability Status Scale showed significant positive associations with 
PC C20:2n-6, PE C20:3n-6 and PC C18:0 as well as a near-significant positive association 
with PE C16:0 quantified in relative percentages, but not with absolute amounts in red 
blood cell membranes from patients.  In contrast, it showed a significant inverse correlation 
with PS C22:5n-3 quantified in relative percentages in red blood cell membranes from 
patients. 
3.4.3 Peripheral blood mononuclear cell membrane fatty acids 
The Kurtzke Expanded Disability Status Scale showed no significant associations with the 
fatty acids in peripheral blood mononuclear cell membranes from patients, but a near-
significant inverse correlation with PE C20:5n-3 quantified in relative percentages. 
4. Discussion 
The objective was to establish whether using absolute amounts in quantifying fatty acids in 
biological tissue would provide sufficient information to investigate abnormalities in a 
diseased state, in this case investigating the fatty acid profile in patients with multiple 
sclerosis. Results showed that correlation strengths between fatty acids quantified in 
absolute amounts and relative percentages varied in some instances in plasma, red blood 
cell as well as peripheral blood mononuclear cell membranes between study groups (Table 
2). Furthermore, even when a correlation was observed between absolute amounts and 
relative percentages the R value was not always close to the value one as would have been 
expected if these theoretically represent each other. Of note is that some of these correlations 
were lost or gained in diseased subjects. For example, PC C18:1n-9 showed stronger 
correlations in peripheral blood mononuclear cells from patients, than in control subjects. In 
contrast, PS C22:4n-6 showed significance in red blood cell membranes from controls, but 
not in patients with multiple sclerosis (Figure 1). 
 
    
Fig. 1. Measurement comparison of PS C22:4n-6 quantified in absolute amounts and relative 
percentages in red blood cell membranes. Controls, R = 0.74; P = < 0.0000. In patients with 
multiple sclerosis the correlation was not significant, R = 0.18; P = 0.3413.  
www.intechopen.com
 
Gas Chromatography – Biochemicals, Narcotics and Essential Oils 
 
152 
Multiple sclerosis is an inflammatory disease of the central nervous system in which an 
abnormal fatty acid profile has been reported, but with inconclusive findings (Cherayil, 
1984; Navarro & Segura, 1989; Harbige & Sharief, 2007; Hon et al., 2009a, 2009b). The n-6 
and n-3 polyunsaturated fatty acids, C18:2n-6, C20:4n-6 and C20:5n-3 have been reported to 
be decreased in plasma and blood cell membranes from these patients (Baker et al., 1964; 
Cherayil, 1984; Holman et al., 1989; Nightingale et al., 1990; Hon et al., 2009a, 2009b), but 
other research groups have found no differences compared to control subjects (Cumings et 
al., 1965; Fisher et al., 1987; Evans & Dodd, 1989; Koch et al., 2006). Disturbed metabolic 
relationships between C18:2n-6 and C20:3n-6 (Harbige & Sharief, 2007), as well as between 
C20:3n-6 and C20:4n-6 (Harbige & Sharief, 2007; Hon et al., 2009b) in the peripheral blood 
mononuclear cell membranes from patients with multiple sclerosis have also been reported. 
Homa et al. (1980) showed the relationship between C18:2n-6 and C20:4n-6 in red blood 
cells from patients to be disturbed, while Hon et al. (2009a) reported disturbances between 
PC C18:2n-6 and PC C20:3n-6, PC C18:2n-6 and PC C20:4n-6, PC C20:3n-6 and PC C20:4n-6 
in red blood cells from patients. The lack of consensus on the role of fatty acids in the 
pathogenesis of multiple sclerosis, may be due to the variable results observed in previous 
studies which may be attributed to the different forms of assessments used (absolute 
amounts and relative percentages).  
4.1 Quantification of polyunsaturated fatty acid C20: 4n-6 
The n-6 polyunsaturated fatty acid PC C20:4n-6 (data not shown) showed significant 
correlations between absolute amounts and relative percentage composition in plasma from 
both the control group and patients with multiple sclerosis, but showed a wide variation in 
red blood cell membranes. PE C20:4n-6 showed a weak correlation in controls only, while 
PS C20:4n-6 in contrast showed a strong correlation in red blood cells from patients. PE 
C20:4n-6 showed a strong correlation in peripheral blood mononuclear cell membranes from 
patients and a weak correlation in controls. In contrast to the differences in correlations 
between absolute amounts and relative percentage composition of C20:4n-6 in red blood cell 
and peripheral blood mononuclear cell membranes from patients with that of the control 
group, the n-3 polyunsaturated fatty acids in general showed similar strong associations 
between absolute amounts and relative percentage in plasma, red blood cell and peripheral 
blood mononuclear cell membranes from controls and patients (Table 2). These results have 
demonstrated that in control subjects there is a wide range of association strengths between 
the n-6 fatty acids quantified in absolute amounts and relative percentages with these 
associations being further disturbed in patients with multiple sclerosis. On the other hand, 
the n-3 polyunsaturated fatty acids showed close associations between absolute amounts 
and relative percentages and that this was maintained in patients with multiple sclerosis.  
It is unclear why the n-6 polyunsaturated fatty acid C20:4n-6 should show such a wide 
variation in association between absolute amounts and relative percentages (from very weak 
to strong) in plasma, red blood cell and peripheral blood mononuclear cell membranes from 
controls. Furthermore, it is unclear why C20:4n-6 should have stronger associations between 
absolute amounts and relative percentages  specifically in peripheral blood mononuclear 
cell membranes from patients, unless the reversal of association strength in these immune 
cells are part of the pathogenesis of multiple sclerosis. C20:4n-6 is released from cell 
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membranes during inflammation as precursor for pro-inflammatory prostaglandin E2 
production (Horrobin & Manku, 1990; Simopoulos, 2002; Bagga et al., 2003; Haag, 2003), 
while its precursor fatty acid in the n-6 fatty acid series, C20:3n-6 is the precursor fatty acid 
for the synthesis of prostaglandin E1, a less inflammatory mediator of inflammation, than 
prostaglandin E2. In contrast, prostaglandin E3 derived from the metabolism of C20:5n-3 
and docosanoids derived from the metabolism of C22:6n-3 has anti-inflammatory properties 
(Bagga et al., 2003; Haag, 2003; Zamaria, 2004; Farooqui et al., 2007; Chen et al., 2008). In a 
disease such as multiple sclerosis, which is inflammatory in nature, it is useful to know 
whether the n-6 and n-3 polyunsaturated fatty acids show any metabolic abnormalities and 
these results suggested abnormalities within the n-6 polyunsaturated fatty acid series rather 
than in the n-3 polyunsaturated fatty acids.  
Results from previous studies (Hon et al., 2009a, 2009b; Hon et al., 2011a) and this study 
showed similar decreases in polyunsaturated fatty acid C20:4n-6 and its elongation product 
C22:4n-6 when quantified in absolute amounts or relative percentages in plasma, red blood 
cell and/or peripheral blood mononuclear cell membranes from patients with multiple 
sclerosis as compared to controls. Therefore, investigating measures of central tendencies in 
fatty acids from control subjects and patients with multiple sclerosis using both 
quantifications methods does not explain the differences in reports of C20:4n-6 composition 
in patients with multiple sclerosis as compared to control subjects. However, the variations 
in association strengths between C20:4n-6 quantified in absolute amounts and relative 
percentages in patients compared to control subjects (Table 2) showed that other factors 
must contribute to the change in association. In this regard, the C-reactive protein has been 
shown to correlate inversely with PE C20:4n-6 and PE C22:4n-6 quantified in absolute values 
in red blood cell membranes from patients with multiple sclerosis (Hon et al., 2009a) and 
also inversely with PC C20:4n-6, PS C20:4n-6, PS C22:4n-6 and PI C22:4n-6 quantified in 
absolute values in peripheral blood mononuclear cell membranes from patients with 
multiple sclerosis (Hon et al., 2009b). It is possible therefore to expect C-reactive protein 
concentrations to show associations with blood fatty acids depending on the inflammatory 
status of the patients. 
4.2 Association between C-reactive protein and polyunsaturated fatty acids  
In this study, results (Table 3) showed that the C-reactive protein showed very few 
associations with fatty acids quantified in absolute amounts in plasma, red blood cell or 
peripheral blood mononuclear cell membranes from either control subjects or patients with 
multiple sclerosis. In contrast, it showed a number of associations with fatty acids quantified 
in relative percentages in both controls and patients. Furthermore, these results indicated 
that the association between the C-reactive protein and certain fatty acids quantified in 
relative percentages are valid, because the same associations were found in plasma and red 
blood cell membrane fatty acids. For example, the C-reactive protein showed positive 
associations with PC C20:3n-6 quantified in absolute amounts as well as in relative 
percentages in plasma from patients but an association in plasma from controls only with 
this fatty acid quantified in relative percentages. The same association was found between 
the C-reactive protein and PC C20:3n-6 quantified in relative percentages in red blood cells 
from controls and patients but not in peripheral blood mononuclear cell membranes from 
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patients or controls. These and previous results showed that association and correlation 
studies between the C-reactive protein and fatty acids as well as using absolute amounts 
and relative percentages of fatty acids in evaluating their role in inflammation in patients 
with multiple sclerosis gave different outcomes, and that relative percentages gave 
additional information. Specifically, these results showed that correlation studies 
highlighted the inverse correlations between the C-reactive protein and C20:4n-6 as well as 
C22:4n-6 quantified in absolute amounts in patients, while association studies showed a 
positive association between C-reactive protein and C20:3n-6 and that this association was 
found primarily with the relative percentages.  
These results are important because C20:4n-6 and C20:3n-6 are precursors for 
prostaglandins E2 and E1 respectively and of these E1 is the less inflammatory mediator, 
and clearly, the C-reactive protein showed opposite correlations/associations with these  
two fatty acids. It is not clear from the results of this study whether the positive association 
between the C-reactive protein and C20:3n-6 was due to the membrane content of the fatty 
acid or whether it was due to the amount made available for prostaglandin E2 production, 
that is whether a higher membrane content suggested lower levels of the less inflammatory 
prostaglandin. However, fatty acid metabolic abnormalities have been reported between 
C20:3n-6 and C20:4n-6 in the peripheral blood mononuclear cell (Harbige & Sharief, 2007; 
Hon et al., 2009b) and red blood cell (Hon et al., (2009a) membranes from patients.  
4.3 Association between C-reactive protein and monounsaturated fatty acids  
Furthermore, the C-reactive protein showed positive associations with PC C16:1n-7 
quantified in relative percentages in plasma from controls and with PC C16:1n-7 quantified 
in both absolute amounts (Hon et al., 2010) and relative percentages in both red blood cell 
and peripheral blood mononuclear cell membranes from controls (Table 3). In contrast, it 
showed no association with PC C16:1n-7 in any of these blood compartments from patients. 
The associations between the C-reactive protein and monounsaturated fatty acid C16:1n-7 in 
control subjects suggested a specific role for this fatty acid in the immune cells in the 
inflammatory process. The absence of this association in patients suggested an irregularity 
in the immune process in patients with multiple sclerosis. The C-reactive protein did show a 
positive association with PC C18:1n-7 in peripheral blood mononuclear cell membranes 
from patients but only with the percentage composition. 
In contrast to the positive associations with the n-7 fatty acids, the C-reactive protein 
showed an inverse association with PC C18:1n-9 quantified in relative percentages in 
plasma and red blood cells from patients, but in peripheral blood mononuclear cell 
membranes from controls only. These results again showed the importance of including 
relative percentages when evaluating the relationship between inflammation and fatty acids 
in patients with multiple sclerosis. Monounsaturated fatty acids may have anti-
inflammatory effects, although their role in inflammation is not as well defined as that of the 
polyunsaturated fatty acids (Yaqoob et al., 1998; Harwood & Yaqoob, 2002). The results 
from this and previous studies showed that the altered associations between the C-reactive 
protein and the n-7 and n-9 monounsaturated fatty acids may have had an effect on their 
anti-inflammatory functions  and may therefore have contributed to the pathogenesis of the 
disease. 
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4.4 The relationship between polyunsaturated fatty acids and the Kurtzke Expanded 
Disability Status Scale 
Previous studies have shown an inverse correlation between the Kurtzke Expanded 
Disability Status Scale and PC C20:4n-6 quantified in absolute values in red blood cell 
membranes from patients (Hon et al., 2009a), but a positive correlation with PC C20:3n-6 in 
peripheral blood mononuclear cell membranes from patients with multiple sclerosis (Hon et 
al., 2009b). Results from this study showed no association between the Kurtzke Expanded 
Disability Status Scale and C20:4n-6, but it did show positive associations with PC C20:2n-6 
and PE C20:3n-6 quantified in relative percentages in red blood cell from patients (Table 4). 
These findings are important because the C-reactive protein has been shown in previous 
studies to show inverse correlations with C20:4n-6 quantified in absolute amounts in 
patients, while a positive association was shown in this study with PC C20:3n-6 quantified 
in relative percentages in peripheral blood mononuclear cell membranes from patients. 
Furthermore, previous studies have shown that the C-reactive protein also showed a 
positive correlation with the Kurtzke Expanded Disability Status Scale in patients with 
multiple sclerosis (Hon et al., 2009b).  
Although these results would need further investigation, their associations/correlations would 
suggest that with an increase in the C-reactive protein, there is a decrease in blood cell 
membrane C20:4n-6 and an increase in C20:3n-6, with an accompanying  increase in the 
Kurtzke Expanded Disability Status Scale in patients with multiple sclerosis. It is possible to 
hypothesize that the decrease in membrane C20:4n-6 could have been due to the release of this 
fatty acid for eicosanoid production because this fatty acid is the major fatty acid to be released 
for eicosanoid production during the inflammatory processes, as measured by the C-reactive 
protein (Calder, 2007). In addition, these results further suggested that an imbalance in C20:4n-
6 and C20:3n-6 release for prostaglandin E2 and E1 production respectively could be 
associated with the inflammatory condition experienced by patients with multiple sclerosis 
and that this effect could possibly be a constant condition, hence the significant 
correlation/association with the Kurtzke Expanded Disability Status Scale respectively. 
4.5 Membrane phospholipids 
Membrane lipids consist of phospholipids, into which saturated and unsaturated fatty acids 
are incorporated, as well as cholesterol. Choline containing phospholipids, 
phosphatidylcholine and sphingomyelin are mainly on the outer leaflet of plasma 
membranes, while phosphatidylethanolamine and phosphatidylserine are located on the 
inner leaflet. The properties of the different phospholipid molecules depend on their 
different head-groups as well as on the type of fatty acids they contain (Williams, 1998; 
Horrobin, 1999) and their composition in cell membranes determines the degree of fluidity 
of the membrane structures. Phospholipids from both red blood cell (Hon et al., 2009c) and 
peripheral blood mononuclear cell (Hon et al., 2011b) membranes have been reported in 
detail and specifically their function in determining cell membrane fluidity and their role in 
disease outcome in patients with multiple sclerosis.  
5. Conclusions 
The validity of using fatty acid composition in relative percentages and/or absolute 
amounts has been discussed with regards to measurements of these in the blood 
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components of patients with multiple sclerosis, an inflammatory disease of the central 
nervous system, in which various fatty acid imbalances have been described, but without 
any firm conclusions as to cause or consequences. The results of this study showed that 
using a combination of fatty acids quantified in both absolute amounts and relative 
percentages could be relevant, especially in a disease state such as multiple sclerosis. This 
was further confirmed by the association between C-reactive protein, a marker of 
inflammation and the fatty acids. Therefore, it is recommended that fatty acids should be 
analysed and interpreted using both absolute amounts and relative percentages. 
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